These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
435 related articles for article (PubMed ID: 29331844)
1. Assessing the risk of CMV reactivation and reconstitution of antiviral immune response post bone marrow transplantation by the QuantiFERON-CMV-assay and real time PCR. Krawczyk A; Ackermann J; Goitowski B; Trenschel R; Ditschkowski M; Timm J; Ottinger H; Beelen DW; Grüner N; Fiedler M J Clin Virol; 2018; 99-100():61-66. PubMed ID: 29331844 [TBL] [Abstract][Full Text] [Related]
2. Quantiferon-Cytomegalovirus assay: A potentially useful tool in the evaluation of CMV-specific CD8+ T-cell reconstitution in pediatric hematopoietic stem cell transplant patients. Paouri B; Soldatou A; Petrakou E; Theodosaki M; Tsentidis C; Kaisari K; Oikonomopoulou C; Matsas M; Goussetis E Pediatr Transplant; 2018 Aug; 22(5):e13220. PubMed ID: 29777573 [TBL] [Abstract][Full Text] [Related]
3. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital. Fleming T; Dunne J; Crowley B J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937 [TBL] [Abstract][Full Text] [Related]
4. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients. Gliga S; Korth J; Krawczyk A; Wilde B; Horn PA; Witzke O; Lindemann M; Fiedler M J Clin Virol; 2018 Aug; 105():91-96. PubMed ID: 29936407 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients. Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338 [TBL] [Abstract][Full Text] [Related]
6. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation. Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633 [TBL] [Abstract][Full Text] [Related]
7. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. Tey SK; Kennedy GA; Cromer D; Davenport MP; Walker S; Jones LI; Crough T; Durrant ST; Morton JA; Butler JP; Misra AK; Hill GR; Khanna R PLoS One; 2013; 8(10):e74744. PubMed ID: 24146744 [TBL] [Abstract][Full Text] [Related]
8. Functional specific-T-cell expansion after first cytomegalovirus reactivation predicts viremia control in allogeneic hematopoietic stem cell transplant recipients. Ciáurriz M; Beloki L; Zabalza A; Bandrés E; Mansilla C; Pérez-Valderrama E; Lachén M; Rodríguez-Calvillo M; Ramírez N; Olavarría E Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921749 [TBL] [Abstract][Full Text] [Related]
9. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414 [TBL] [Abstract][Full Text] [Related]
10. Low cytomegalovirus-specific T-cell counts at reactivation are associated with progression to high-level viremia or disease in seropositive recipients of hematopoietic cell grafts from seropositive but not seronegative donors. Hoegh-Petersen M; Roa L; Liu Y; Zhou F; Ugarte-Torres A; Louie P; Fonseca K; Khan F; Russell JA; Storek J Cytotherapy; 2012 Feb; 14(2):194-204. PubMed ID: 22149135 [TBL] [Abstract][Full Text] [Related]
14. Kinetics of interferon-gamma producing cytomegalovirus (CMV)-specific CD4+ and CD8+ T lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation. Eid AJ; Brown RA; Hogan WJ; Lahr BD; Eckel-Passow JE; Litzow MR; Razonable RR Transpl Infect Dis; 2009 Dec; 11(6):519-28. PubMed ID: 19744286 [TBL] [Abstract][Full Text] [Related]
15. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction. Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310 [TBL] [Abstract][Full Text] [Related]
16. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Zhou W; Longmate J; Lacey SF; Palmer JM; Gallez-Hawkins G; Thao L; Spielberger R; Nakamura R; Forman SJ; Zaia JA; Diamond DJ Blood; 2009 Jun; 113(25):6465-76. PubMed ID: 19369230 [TBL] [Abstract][Full Text] [Related]
17. Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status. Servais S; Dumontier N; Biard L; Schnepf N; Resche-Rigon M; Peffault de Latour R; Scieux C; Robin M; Meunier M; Xhaard A; Sicre de Fontbrune F; Le Goff J; Socié G; Simon F; Mazeron MC Clin Microbiol Infect; 2016 Mar; 22(3):289.e1-7. PubMed ID: 26627339 [TBL] [Abstract][Full Text] [Related]
18. Protective immunity transferred by infusion of cytomegalovirus-specific CD8(+) T cells within donor grafts: its associations with cytomegalovirus reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation. Luo XH; Huang XJ; Liu KY; Xu LP; Liu DH Biol Blood Marrow Transplant; 2010 Jul; 16(7):994-1004. PubMed ID: 20167279 [TBL] [Abstract][Full Text] [Related]
19. Expansion of effector memory Vδ2 Huang Y; Jiang C; Zhu J; Lin L; Mao M; Yin T; Cai G Front Immunol; 2024; 15():1397483. PubMed ID: 38915409 [TBL] [Abstract][Full Text] [Related]
20. Timing of CMV-specific effector memory T cells predicts viral replication and survival after allogeneic hematopoietic stem cell transplantation. Espigado I; de la Cruz-Vicente F; BenMarzouk-Hidalgo OJ; Gracia-Ahufinger I; Garcia-Lozano JR; Aguilar-Guisado M; Cisneros JM; Urbano-Ispizua A; Perez-Romero P Transpl Int; 2014 Dec; 27(12):1253-62. PubMed ID: 25070273 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]